LY3650150 + Placebo + Standard therapy for INCS
Phase 3Recruiting 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Perennial Allergic Rhinitis (PAR)
Conditions
Perennial Allergic Rhinitis (PAR)
Trial Timeline
Apr 26, 2024 โ Oct 1, 2028
NCT ID
NCT06339008About LY3650150 + Placebo + Standard therapy for INCS
LY3650150 + Placebo + Standard therapy for INCS is a phase 3 stage product being developed by Eli Lilly for Perennial Allergic Rhinitis (PAR). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06339008. Target conditions include Perennial Allergic Rhinitis (PAR).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06338995 | Phase 3 | Recruiting |
| NCT06339008 | Phase 3 | Recruiting |
Competing Products
20 competing products in Perennial Allergic Rhinitis (PAR)